Australian Menopause Experts Support Change in Hormone Therapy Warnings
14 November 2025:
The Australasian Menopause Society (AMS) has urged women to continue seeking advice from their doctor about the possible risks of menopausal hormone therapy (MHT) in the wake of a U.S Food and Drug Administration (FDA) decision to remove the black box warning.
AMS President, Dr Christina Jang said the FDA’s action acknowledges a current understanding that the risks of MHT have previously been overstated.
Dr Jang said the AMS would support a TGA review of the product and consumer information relating to MHT products in Australia.
“There are a range of MHT products available in Australia. Different formulations carry different risk profiles; for the majority of women benefits of MHT outweigh the risks”
“We don’t have long term safety data for modern MHT preparations, so women should still discuss individual risks with their doctor,” Dr Jang said.
“MHT is highly effective for the treatment of menopause symptoms and the decision to use MHT should be based on a discussion between the woman and her doctor considering her personal risk versus benefit profile.” Dr Jang said.
The FDA imposed a black box warning on all MHT products in 2003 in the wake of headlines regarding potential risks.
~Ends~
Australian Menopause Experts Support Change in Hormone Therapy Warnings142 KB
AMS President Dr Christina Jang is available for interview. For media enquiries, please contact Chris Michaelides, Executive Director at